Skip to main content
SpringerLink
Log in

Efficacy and Safety of Statins in Older Adults

  • Elderly and Cardiovascular Disease (DE Forman and JM Gaziano)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Cardiovascular disease remains the leading cause of death in the United States, with the greatest burden borne by adults above 65 years of age. HMG-CoA-reductase inhibitors, or statins, have been demonstrated to greatly reduce morbidity and mortality in patients with established cardiovascular disease, yet their rates of utilization in older adults remain relatively low. In addition, few trials have specifically analyzed the efficacy of statins in older patients. This review summarizes the data relevant to the use of statins for the primary and secondary prevention of cardiovascular disease in older adults as well as some of the controversies regarding possible links between statins and cognitive impairment or diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Centers for Disease Control and Prevention. Prevalence of Heart Disease-United States (2005). Available at http://www.cdc.gov/DataStatistics/archive/heartdisease.html. Accessed April 2012.

  2. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125:188–97.

    Article  PubMed  Google Scholar 

  3. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005;96:24F–33F.

    Article  PubMed  CAS  Google Scholar 

  4. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38–44.

    Article  PubMed  CAS  Google Scholar 

  5. Setoguchi S, Glynn RJ, Avorn J, et al. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age. Am J Cardiol. 2007;100:1061–7.

    Article  PubMed  Google Scholar 

  6. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864–70.

    Article  PubMed  CAS  Google Scholar 

  7. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data. Arch Intern Med. 1993;153:1065–73.

    Article  PubMed  CAS  Google Scholar 

  8. Weverling-Rijnsburger AWE, Blau GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119–23.

    Article  PubMed  CAS  Google Scholar 

  9. Shipley MJ, Pocock SJ, Marmot MG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? Eighteen-year follow-up in Whitehall study. BMJ. 1991;303:89–92.

    Article  PubMed  CAS  Google Scholar 

  10. Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med. 1997;126:753–60.

    PubMed  CAS  Google Scholar 

  11. Schatz IJ, Masaki K, Yano K, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet. 2001;358:351–5.

    Article  PubMed  CAS  Google Scholar 

  12. Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–39.

    Article  PubMed  Google Scholar 

  13. Arnold SV, Rich MW. Hyperlipidemia in older adults. Clinical Geriatrics. 2009;2–8.

  14. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–30.

    Article  PubMed  CAS  Google Scholar 

  15. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled tria. Lancet. 2003;361:1149–58.

    Article  PubMed  CAS  Google Scholar 

  16. Sever PS, Poulter NR, Bahlof B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J. 2008;29:499–508.

    Article  PubMed  CAS  Google Scholar 

  17. Sever PS, Chang CL, Gupta AK, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J. 2011;32:2525–32.

    Article  PubMed  CAS  Google Scholar 

  18. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29:2378–84.

    Article  PubMed  CAS  Google Scholar 

  19. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488–96.

    PubMed  Google Scholar 

  20. •• Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. This meta-analysis found statistically significant reductions in all-cause mortality, major coronary events, and in major cerebrovascular events with the use of statins for the primary prevention of cardiovascular disease in people with cardiovascular risk factors. There was no increase in cancer incidence with statin use

    Article  PubMed  CAS  Google Scholar 

  21. Maycock CAA, Muhlestein JB, Horne BD, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol. 2002;40:1777–85.

    Article  Google Scholar 

  22. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥ 125 mg/dL treated with statins vs no lipid-lowering drug. Am J Cardiol. 2002;89:67–9.

    Article  PubMed  CAS  Google Scholar 

  23. Foody JM, Rathore SS, Galusha D, et al. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Soc. 2006;54:421–30.

    Article  PubMed  Google Scholar 

  24. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4 S). Circulation. 1997;96:4211–8.

    Article  PubMed  CAS  Google Scholar 

  25. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129:681–9.

    PubMed  CAS  Google Scholar 

  26. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37–45.

    Article  PubMed  CAS  Google Scholar 

  27. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to, or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134:931–40.

    PubMed  CAS  Google Scholar 

  28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22.

    Article  Google Scholar 

  29. Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007;147:1–9.

    PubMed  Google Scholar 

  30. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80 + -year olds. Age Ageing. 2010;39:674–80. Epub 2010 Oct 14.

    Article  PubMed  Google Scholar 

  31. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387–92.

    Article  PubMed  CAS  Google Scholar 

  32. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.

    Article  Google Scholar 

  33. Hackam DG, Austin PC, Huang A, et al. Statins and intracerebral hemorrhage: a retrospective cohort study. Arch Neurol. 2012;69:39–45. Epub 2011 Sep 12.

    Article  PubMed  Google Scholar 

  34. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439–43.

    Article  PubMed  CAS  Google Scholar 

  35. Haag MD, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity: The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80:13–7. Epub 2008 Oct 17.

    Article  PubMed  CAS  Google Scholar 

  36. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:78–86.

    Article  PubMed  CAS  Google Scholar 

  37. King DS, Wilburn AJ, Wofford MR, et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy. 2003;23:1663–7.

    Article  PubMed  Google Scholar 

  38. Galatti L, Polimeni G, Salvo F, et al. Short-term memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26:1190–2.

    Article  PubMed  Google Scholar 

  39. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29:800–11.

    Article  PubMed  CAS  Google Scholar 

  40. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871–80.

    Article  PubMed  Google Scholar 

  41. Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823–9.

    Article  PubMed  CAS  Google Scholar 

  42. FDA Drug Safety Communication. Important safety label changes to cholesterol-lowering statin drugs. Available at http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed April 2012.

  43. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788–97.

    Article  PubMed  CAS  Google Scholar 

  44. Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res. 2009;153:11–6. Epub 2008 Dec 6.

    Article  PubMed  CAS  Google Scholar 

  45. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005;62:1709–12.

    Article  PubMed  Google Scholar 

  46. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408–16.

    Article  PubMed  CAS  Google Scholar 

  47. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99:1409–12. Epub 2007 Apr 3.

    Article  PubMed  CAS  Google Scholar 

  48. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231–7.

    Article  PubMed  CAS  Google Scholar 

  49. • Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. This large meta-analysis of statin trials documents the proportional reductions in all-cause mortality and major cardiovascular events achieved with LDL reduction while describing the overall safety of statins in the populations studied

    Article  PubMed  CAS  Google Scholar 

  50. •• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–42. Epub 2010 Feb 16. This paper reported a significantly increased risk of incident diabetes with statin therapy, although the absolute risk was relatively low. The increase in risk was greater in older patients

    Article  PubMed  CAS  Google Scholar 

  51. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172:144–52. Epub 2012 Jan 9.

    Article  PubMed  Google Scholar 

  52. • Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64. This meta-analysis found a dose-dependent relationship between statin use and risk of new-onset diabetes

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Cardiology Division, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8086, St. Louis, MO, 63110, USA

    Justin S. Sadhu & Michael W. Rich

Authors
  1. Justin S. Sadhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael W. Rich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. Rich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sadhu, J.S., Rich, M.W. Efficacy and Safety of Statins in Older Adults. Curr Cardiovasc Risk Rep 6, 372–379 (2012). https://doi.org/10.1007/s12170-012-0256-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-012-0256-y

Keywords

Search

Navigation